NCT02347228View on ClinicalTrials.gov

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Solid Malignancies
Interventions
DRUG

OB318 capsule

Oral qd, at least 30 minutes before breakfast

Trial Locations (2)

114

RECRUITING

Tri-Service General Hospital, Taipei

Unknown

RECRUITING

Taipei Medical University-Shuang Ho Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Oneness Biotech Co., Ltd.

INDUSTRY